Latest Market Access News

LTR Pharma has completed the final Phase II pharmacokinetic report for SPONTAN, confirming a median 10-minute time to peak concentration against 60 minutes for an oral vardenafil tablet. The result completes the FDA-aligned dataset ahead of planned US submission work, although efficacy in erectile dysfunction patients remains to be tested.

FortifAI has emerged from its first year as an AI infrastructure company with $20.4 million in cash, but a $29 million statutory loss and sharply lower gaming revenue. The company now needs to turn NOL8’s early testing and partnerships into commercial adoption before its cash-backed growth strategy faces a harder test.

Sultan Resources has reported a $1.48 million FY2026 loss and an auditor-highlighted material uncertainty over its ability to continue as a going concern. The explorer is seeking to fund early-stage Lachlan Fold Belt work while pursuing a new Namibia opportunity and a post-year-end $1.316 million placement.

SciDev Limited (ASX:SDV) finished FY26 with a sharp annual earnings decline, but a leaner business and stronger second-half performance offer a potential reset. Revenue fell 17% and underlying EBITDA dropped 49%, while the company exited loss-making international operations and rebuilt net cash to $6.8 million.

Sea Forest has reported a sharp lift in SeaFeed revenue during its first full year as an ASX-listed company, but remains loss-making as it funds production and market expansion. The methane-reduction specialist ended FY26 with $27.8 million in cash and term deposits and no borrowings.

EMVision Medical Devices has received a $4.3 million R&D tax refund, adding non-dilutive funding as it progresses clinical work on its emu™ and First Responder devices. The cash arrives against a last reported cash balance of $17.1 million and $4.6 million in remaining grant funding at 30 June 2026.

American Tungsten & Antimony has submitted a confidential draft Form F-1 to US regulators, moving its proposed Level III ADR listing on Nasdaq into formal review. The company also extended the Del Sol transaction end date by three weeks, leaving both major initiatives progressing but unfinished.

First Graphene expanded its product range and international footprint in FY2026, lifting revenue while narrowing its annual loss. But the company says continued operations depend on securing further equity funding, putting commercial execution and liquidity at the centre of its next phase.

Trading in Arrow Minerals securities has been temporarily paused by ASX Supervision pending a further announcement. The notice does not disclose the reason for the pause, its expected duration or the subject of the forthcoming update.

Titomic has set 30 November 2026 as its current target to complete a proposed move of its parent company from Australia to the United States. The ASX listing would remain, but investors would hold CHESS Depositary Interests in the new US entity if shareholders, the Court and other conditions approve the scheme.

PainChek grew recurring revenue, implemented licences and customer sites in FY2026, but its $8.94 million loss and $9.24 million operating cash outflow prompted an explicit going-concern warning from its auditor. The company is now betting that US deployments and a sharper commercial focus can convert market access into cash-generating growth.

Dimerix has drawn A$17 million from a non-dilutive facility, giving the biotech funding it says is sufficient to complete the ACTION3 Phase 3 trial of DMX-200 and continue developing DMX-652. A further A$17 million remains available, although repayment depends partly on future licensing income, milestones or capital-market access.